OVITRELLE 250mcg Injection/Powder for

What is OVITRELLE 250mcg

p>OVITRELLE 250mcg is a medication used in assisted reproductive technologies (ART) such as in vitro fertilization (IVF). It contains Choriogonadotropin alfa, a recombinant human chorionic gonadotropin (hCG) that mimics the natural hormone's action in the body. OVITRELLE is used to trigger ovulation and promote the final maturation of follicles in women undergoing fertility treatments.

How to use OVITRELLE 250mcg

p>OVITRELLE 250mcg is administered via injection, typically subcutaneously. The powder form of the medication needs to be reconstituted with the provided solvent before injection. Here's a general overview of the steps:

• Reconstitution: Mix the powder with the solvent according to the instructions provided.
• Administration: Inject the reconstituted solution subcutaneously, usually in the abdominal wall or thigh.
• Timing: The injection is typically given when the follicles have reached the appropriate size, as determined by ultrasound.

It's essential to follow the specific instructions provided by your healthcare provider for reconstituting and administering OVITRELLE.

Mode of Action OVITRELLE 250mcg

p>Choriogonadotropin alfa in OVITRELLE 250mcg works by mimicking the action of natural luteinizing hormone (LH) surge, triggering ovulation and promoting the final maturation of follicles. This leads to:

• Ovulation Induction: OVITRELLE triggers the release of an egg from the follicle.
• Follicular Maturation: It promotes the final maturation of follicles, increasing the chances of successful fertilization.

This mechanism of action is crucial for the success of fertility treatments like IVF.

OVITRELLE 250mcg Interactions OVITRELLE 250mcg

p>OVITRELLE 250mcg can interact with other medications or worsen certain medical conditions. Some potential interactions include:

• Gonadotropin-Releasing Hormone (GnRH) Agonists or Antagonists: Used in conjunction with OVITRELLE in fertility treatments.
• Other Fertility Medications: OVITRELLE may be used in combination with other fertility medications, and the interactions should be monitored by a healthcare provider.

Always inform your healthcare provider about all the medications you are taking to avoid potential interactions.

Dosage of OVITRELLE 250mcg

p>The recommended dosage of OVITRELLE 250mcg is typically:

• One vial (250mcg) administered subcutaneously, usually 24-48 hours after the last dose of follicle-stimulating hormone (FSH) or human menopausal gonadotropin (hMG).

The exact dosage and timing may vary based on individual patient needs and response to treatment, as determined by a healthcare provider.

Possible side effects of OVITRELLE 250mcg

p>While generally well-tolerated, OVITRELLE 250mcg can cause some side effects, including:

• Ovarian Hyperstimulation Syndrome (OHSS): A potentially serious condition characterized by enlarged ovaries and fluid accumulation in the abdomen and chest.
• Injection Site Reactions: Pain, redness, or swelling at the injection site.
• Nausea and Vomiting: Some women may experience nausea or vomiting after administration.
• Headache: Mild to moderate headaches can occur.

If any side effects persist or worsen, consult your healthcare provider for guidance.

OVITRELLE 250mcg Contraindications OVITRELLE 250mcg

p>OVITRELLE 250mcg is contraindicated in certain individuals due to potential health risks. The contraindications include:

• Hypersensitivity: Individuals known to be hypersensitive to Choriogonadotropin alfa or any other ingredient in the formulation should not use OVITRELLE.
• Primary Ovarian Failure: Women with primary ovarian failure should not use OVITRELLE.
• Uncontrolled Thyroid or Adrenal Dysfunction: Women with uncontrolled thyroid or adrenal dysfunction should not use OVITRELLE.
• Ovarian Enlargement or Cysts: Women with ovarian enlargement or cysts not related to polycystic ovary syndrome (PCOS) should not use OVITRELLE.
• Gynecological Bleeding of Unknown Origin: Women with gynecological bleeding of unknown origin should not use OVITRELLE.
• Ovarian, Uterine, or Breast Cancer: Women with ovarian, uterine, or breast cancer should not use OVITRELLE.

• Thromboembolic Disorders: Women with a history of thromboembolic disorders should use OVITRELLE with caution.
• Ovarian Hyperstimulation Syndrome (OHSS): Women with a history of OHSS should use OVITRELLE with caution.

Before using OVITRELLE 250mcg, it's crucial to consult with a healthcare provider to ensure it's safe for your specific condition and medical history.

Storage of OVITRELLE 250mcg

Proper storage of OVITRELLE 250mcg is essential to maintain its efficacy and safety:

• Refrigeration: Store the vials in the refrigerator at 2°C to 8°C (36°F to 46°F).
• Protection from Light: Keep the vials in the original package to protect from light.
• Do not Freeze: The powder and solvent should not be frozen.
• Expiry: Do not use OVITRELLE after the expiry date printed on the packaging.

By following these storage guidelines, you can ensure the quality and effectiveness of OVITRELLE 250mcg.